Ernexa Therapeutics Inc. ERNA
Ernexa Therapeutics Inc. (Nasdaq: ERNA) is an oncology drug developer. Its lead program, ERNA-101, is in Pre-clinical for platinum-resistant ovarian cancer. Its next catalyst on record is ERNA-101: First-in-human Phase 1 trial start (investigator-sponsored) (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ERNA-101 — First-in-human Phase 1 trial start (investigator-sponsored) (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ERNA-101 (IL-7/IL-15-secreting iPSC-derived MSCs) | platinum-resistant ovarian cancer (IND-enabling; pre-IND meeting completed Q4 2025) | cell therapy | Pre-clinical |
| ERNA-201 (IL-10-secreting iMSCs) | autoimmune disorders such as rheumatoid arthritis (investigational) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.